AbbVie in deal with Biogen to delay Humira biosimilar U.S. launch to 2023

(Reuters) - AbbVie Inc on Thursday said it signed a deal with Biogen Inc and its joint venture partner Samsung Bioepis that would fend off U.S. competition of their rival version to blockbuster drug Humira until 2023.